Hematopoiesis News 7.40 October 11, 2016 | |
| |
TOP STORYMicroenvironment-Dependent Growth of Preneoplastic and Malignant Plasma Cells in Humanized Mice Researchers genetically humanized mice to permit the growth of primary human preneoplastic and malignant plasma cells together with non-malignant cells in vivo. Growth was largely restricted to the bone marrow, mirroring the pattern in patients with myeloma. Xenografts captured the genomic complexity of parental tumors and revealed additional somatic changes. [Nat Med] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Endoglin Integrates BMP and Wnt Signaling to Induce Hematopoiesis through JDP2 Scientists showed that the BMP and Wnt signaling pathways are integrated in an endoglin (Eng)-dependent manner in cardiac and hematopoietic lineage specification. Eng is expressed in early mesoderm and marks both hematopoietic and cardiac progenitors. [Nat Commun] Full Article BLOS2, encoded by the Bloc1s2 gene, is a shared subunit of two lysosomal trafficking complexes, biogenesis of lysosome-related organelles complex-1 (BLOC-1) and BLOC-1 related complex. Bloc1s2-/- mice were embryonic lethal and exhibited defects in cortical development and hematopoiesis. Loss of BLOS2 resulted in elevated Notch signaling, which consequently increased the proliferation of neural progenitor cells and inhibited neuronal differentiation in cortices. [Elife] Full Article The role of Fanconi anemia proteins during hematopoietic development, in the face of physiological replicative demand, remains elusive. The authors revealed a fetal hematopoietic stem and progenitor cells pool in Fancd2−/− mice with compromised clonogenicity and repopulation. [Stem Cell Reports] Full Article Small-Molecule Disruption of the Myb/p300 Cooperation Targets Acute Myeloid Leukemia Cells By using a Myb reporter cell line scientists have identified plumbagin and several naphthoquinones as potent low-molecular weight Myb inhibitors. They demonstrated that these compounds inhibit c-Myb by binding to the c-Myb transactivation domain and disrupting the cooperation of c-Myb with the co-activator p300, a major driver of Myb activity. [Mol Cancer Ther] Abstract Researchers expressed AML1/ETO in a murine immortalized pluripotent hematopoietic stem/progenitor cell line, EML C1, and found that genes involved in functions such as cell-to-cell adhesion and cell motility were among the most significantly regulated as determined by RNA sequencing. [Sci Rep] Full Article CLINICAL RESEARCHHomoharringtonine (Omacetaxine Mepesuccinate) as an Adjunct for FLT3-ITD Acute Myeloid Leukemia A Phase II clinical trial of sorafenib and homoharringtonine combination treatment in internal tandem duplication of fms-like tyrosine kinase 3 (FLT3-ITD) acute myeloid leukemia patients resulted in complete remission (true or with insufficient hematological recovery) in 20 of 24 patients, reduction of ITD allelic burden, and median leukemia-free and overall survivals of 12 and 33 weeks. [Sci Transl Med] Abstract In this prospective Phase II clinical trial conducted by Cancer and Leukemia Group B (CALGB), researchers studied decitabine as maintenance therapy for younger adults with acute myeloid leukemia who remained in first complete remission following intensive induction and consolidation. [Leukemia] Full Article Investigators evaluated whether the presence of circulating tumor DNA was associated with outcome after allogeneic hematopoietic stem cell transplantation in lymphoma patients. [Br J Haematol] Abstract Scientists aimed to identify the role of Cyr61 in regulating acute lymphoblastic leukemia (ALL) cell survival. They found that the level of Cyr61 was increased in the plasma and bone marrow from ALL patients compared with samples from normal control patients. [Sci Rep] Full Article The median age of diagnosis for patients with myeloid malignancies is above 65 years and hematopoietic cell transplantation (HCT) strategies that use reduced-intensity conditioning regimens now allow HCT in older patients with AML and myelodysplastic syndrome. The main principle of these approaches is to decrease regimen-related toxicities by relying mainly on the GvL effect rather than high-dose chemotherapy that kills malignant cells. [Bone Marrow Transplant] Abstract | |
| |
REVIEWSProgress Towards Generation of Human Hematopoietic Stem Cells De novo generation of hematopoietic stem cells from different human pluripotent stem cell sources remains a high priority for hematology and regenerative medicine. At present, efficient derivation of functional hematopoietic stem cells with the capability for definitive in vivo engraftment and multi-lineage potential remains challenging. [Nat Cell Biol] Abstract Hotspots of MLV Integration in the Hematopoietic Tumor Genome The authors discuss the hotspots of murine leukemia retrovirus (MLV) integration into several genes: c-Myc, Stat5a and N-myc, as well as ZFP521, as examined in tumor genomes. [Oncogene] Full Article Visit our reviews page to see a complete list of reviews in the hematopoiesis research field. | |
| |
SCIENCE NEWSBioLineRx Ltd. announced that data on BL-8040, the company’s leading oncology platform, have been accepted for presentations. [Press release from BioLineRx Ltd. discussing research to be presented at 58th American Society of Hematology (ASH) Annual Meeting, San Diego.] Press Release | |
| |
INDUSTRY NEWSDaiichi Sankyo Company, Limited announced that the first patient has been enrolled in the global Phase III QuANTUM-First study evaluating the oral FLT3-ITD inhibitor quizartinib in patients with newly-diagnosed FLT3-ITD-positive acute myeloid leukemia. [Daiichi Sankyo Company, Limited (PR Newswire Association LLC)] Press Release SkylineDx Receives Notice of Allowance to Grant Patent for Prognostic SKY92 Gene Signature in Japan SkylineDx is pleased to announce that it has received a notice of allowance for a Japanese patent related to its prognostic SKY92 gene signature for multiple myeloma. [SkylineDx (PR Newswire Association LLC)] Press Release Gamida Cell Receives FDA Breakthrough Therapy Designation For NiCord® Gamida Cell announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to the company’s lead product candidate, NiCord®, in development as a novel graft modality for bone marrow transplantation in patients with high risk hematological malignancies such as leukemia and lymphoma. [Gamida Cell] Press Release Doernbecher Researchers Awarded More than $9 Million to Fight Fanconi Anemia Thanks to a $9.9 million grant from the National Heart, Lung, and Blood Institute, a team led by Markus Grompe, M.D., director of the Oregon Stem Cell Center at OHSU and the Papé Family Pediatric Research Institute at OHSU Doernbecher Children’s Hospital, will work to understand human response to novel drug treatments that have shown promise in Fanconi anemia-positive animal models. [Oregon Health & Science University] Press Release | |
| |
POLICY NEWSA recruitment and retention program launched by the Howard Hughes Medical Institution in Chevy Chase, Maryland, aims to reduce barriers for women and under-represented minorities who seek academic-research careers in the life sciences. [Nature Careers] Editorial Investors Flee as Firm Scraps RNA-Interference Drug Candidate A prominent developer of drugs that use RNA interference has abandoned one of its leading candidates amid safety concerns — sending a fresh wave of worry through a field that has long struggled to bring treatments to market. [Nature News] Editorial The Many Shades of European Postdoc Funding Finding the right grant or fellowship to fund a postdoc can be a challenge, and the situation is all the more complex in Europe, where academic systems, career prospects, and living costs vary widely among countries. [Science Careers] Editorial
| |
EVENTSNEW Global Forum on Transplantation Research and Technologies Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Scientist – In-Vitro Bone Marrow Toxicity (AstraZeneca) Research Technologist – Hematopoietic Product Development (STEMCELL Technologies) Assistant Member – Pediatric Oncology (Bone Marrow Transplant) Full Member Faculty Hematopoietic Cell Transplant Program (Fred Hutchinson Cancer Research Center) Research Associate – Hematology (Editas Medicine) Faculty – Stem Cell Transplantation and Regenerative Medicine (Stanford University Medical School) Postdoctoral Position – Hematology and Gene Therapy (Cincinnati Children’s Research Foundation) Postdoctoral Position – Leukemia and Marrow Failure (H. Leighton Grimes) Research Fellow – Cancer Biology (University of Michigan) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Hematopoiesis News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|
Home Hematopoiesis News Volume 7.40 | Oct 11 2016